T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas

Summary

This clinical trial studies whether T2 star (T2\*) magnetic resonance imaging (MRI) and biomarker blood testing can help predict how World Health Organization (WHO) grade IV gliomas (malignant gliomas) might change or progress over time.

Interventions

• T2 (Observed)-Weighted Imaging · PROCEDURE

  Undergo T2\* MRI

• Biospecimen Collection · PROCEDURE

  Undergo blood sample collection

• Magnetic Resonance Imaging · PROCEDURE

  Undergo standard MRI

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Age \> 21 years
* New pathologically confirmed diagnosis of WHO grade IV malignant glioma
* KPS \> 60
* Ability to give informed consent for standard of care chemotherapy and radiation therapy on the MR Linac and to study procedures for the protocol

Exclusion Criteria:

* History of previous malignancy other than non-melanoma skin cancer in the previous 5 years
* History of iron metabolic disorder such as hemochromatosis
* Inability to undergo MR studies due to size, claustrophobia, or metal implants or devices

Sites (1)

• University of Iowa Health Care, Iowa City, Iowa · RECRUITING